Safety and Tolerability of Yaq-001 in Patients With Cirrhosis

Liver Cirrhosis Clinical Trial

Official title:

Safety and Tolerability of Yaq-001 in Patients With Cirrhosis ("CARBALIVE-SAFETY")

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03202498
• Other study ID #: Yaq001-S-001
• Status: Terminated
• Phase: N/A
• Start date: February 28, 2019
• Est. completion date: March 26, 2020

Study information

• Verified date: October 2019
• Source: Yaqrit Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In patients with cirrhosis (scarring of the liver), bacterial fragments leak from the gut into the blood and cause harm. This study looks into a new way to lower the leakage of bacterial fragments into the blood.

Yaq-001 is a new type of carbon that in previous laboratory studies has been shown to have the ability to bind these bacterial fragments and so confine them to the gut. The purpose of this clinical trial is to test the product Yaq-001 for the first time in patients with cirrhosis.

This trial will assess if the treatment with Yaq-001 is safe, is well tolerated, and if it helps improve the overall health status of the cirrhotic patients.

Candidate patients must be at least 18 years old and have a clinical diagnosis of cirrhosis for any cause. Only postmenopausal women or with surgical sterilisation are eligible. Additional inclusion and exclusion criteria of medical nature will be determined with the investigator at the screening visit, by means of standard care routines plus an additional test to assess the bowel transit time.

Eligible patients will be randomly grouped to receive standard care treatment plus Yaq-001, or standard treatment plus placebo (non-active treatment). The use of placebo is necessary to better understand how safe and tolerable Yaq-001 really is.

The treatment lasts for 12 weeks. During treatment, the patient will be visited by a study doctor 5 times. At all the visits the patients will undergo a routine physical examination, electrocardiogram, collection of blood and urine samples. On three occasions the patients will be asked to provide additional samples of blood, urine and stool for analysis outside the hospital.

56 patients from 9 hospitals in UK, France, Italy, Portugal, Spain and Switzerland will participate in this study.

Description:

First-in-human clinical investigation with Yaq-001. This is a multicentre, randomized, double blinded, placebo controlled trial to intended to evaluate safety and tolerability of oral administration of Yaq-001 therapy in two dosing cohorts.

56 cirrhotic patients with diuretic-responsive ascites will be enrolled. Patients will be randomized to two dosing cohorts.

Cohort 1 (1:1 randomization)

• Standard medical treatment + Yaq-001 (4 g/ day) - n= 14.

• Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day) - n= 14.

Cohort 2 (1:1 randomization)

• Standard medical treatment + Yaq-001 (8 g/ day) - n= 14.

• Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day) - n= 14.

Study patients will be dosed daily with Yaq-001 (or an equivalent quantity of placebo) for 12 weeks. Assessments of DSMB will take place after 4 and 12 weeks. Investigational centres specialized in the management of patients with liver cirrhosis will participate in the study.

For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.

The total study duration is estimated to be approximately 6 months from screening of first patient until study completion of the last patient.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 634579.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 31
• Est. completion date: March 26, 2020
• Est. primary completion date: March 26, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male and female patients

2. Age = 18 years at screening

3. Clinical diagnosis of cirrhosis for any cause. Liver biopsy is not required

4. Cirrhotic patients with diuretic-responsive ascites and Child-Pugh score = 7-11 inclusive

5. Abstinence from alcohol for at least 4 weeks prior to screening

Exclusion Criteria:

1. Refusal or inability (lack of capacity) to give informed consent

2. Prohibited medication within 4 weeks before the start of the study treatment: all oral antibiotics, immunosuppressants, long acting benzodiazepines or barbiturates and antiviral medication

3. Change in dose of proton pump inhibitor therapy within 4 weeks before the start of the study treatment

4. Patients with once daily medications in which orocaecal transit time is greater than 10 hours

5. Patients requiring medication in which the dosing schedule is three times per day or greater

6. Antiviral therapy for hepatitis C within 3 months prior to screening

7. Hospital admission for liver-related indication for at least 4 weeks (except paracentesis)

8. BMI > 35 or BMI < 18

9. Clostridium Difficile diarrhoea within 4 weeks before the start of the study treatment

10. Uncontrolled infection (chronic viral hepatitis is not an exclusion criterion)

11. Human immunodeficiency virus

12. Presence of a transjugular intrahepatic portosystemic shunt (TIPSS)

13. Participation in any clinical study of an investigational medicinal product within 30 days of five half-lives of the investigational product, whichever is longer

14. Presence of clinically relevant cardiovascular, pulmonary, gastro-intestinal, renal, hepatic, metabolic, haematological, neurological, psychiatric, systemic, ocular, gynaecologic or any acute infection disease or signs of acute illness that, in the opinion of the investigator, might compromise the patient's safe participation in the trial and/or results in a WHO performance status of 2 or more.

15. Presence of the history of cancer within the past 5 years with exception of hepatocellular carcinoma within Milan criteria, adequately treated localised basal cell carcinoma of the skin, in situ cervical carcinoma or solid malignancy surgical excised in total without recurrence for five years.

16. Women of child bearing potential. Only postmenopausal women or with surgical sterilization will be included.

Related Conditions & MeSH terms

• Fibrosis
• Liver Cirrhosis

Intervention

Device:
• 4g Yaq-001
Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.

Other:
• 4g Placebo
Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.

Device:
• 8g Yaq-001
Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.

Other:
• 8g Placebo
Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.

Locations

Country	Name	City	State
France	Hospital Beaujon, Hepatology and Liver Intensive Care,	Clichy
Italy	Policlinico S.Orsola Malpighi, Department of Medical and Surgical Sciences	Bologna
Italy	Azienda Ospedaliera di Padova, Hepatic Emergencies Unit	Padova
Portugal	University Hospital of Santa Maria	Lisbon
Spain	Hospital Clinic of Barcelona , Liver Unit,	Barcelona
Spain	Hospital Vall d'Hebron, Liver Unit	Barcelona
Spain	Hospital Ramon y Cajal, Department of Gastroenterology and Hepatology	Madrid
Switzerland	Inselspital Universitaet Bern, Department for Visceral Surgery and Medicine,	Bern
United Kingdom	Royal Free Hospital, Institute of Liver and Digestive Disease	London

Sponsors (13)

Lead Sponsor

Collaborator

Yaqrit Ltd

A2F Associates Limited, Alpha Bioresearch S.L., Assistance Publique - Hôpitaux de Paris, Azienda Ospedaliera di Padova, Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Hospital Universitari Vall d'Hebron Research Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Servicio Madrileño de Salud, Madrid, Spain, University College, London, University of Bern, University of Brighton, University of Lisbon

Countries where clinical trial is conducted

France,  Italy,  Portugal,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of reported and observed Serious Adverse Events	The percentage of patients experiencing SAEs will be tabulated by arm.	Day 1
Primary	Assessment of treatment-related Serious Adverse Events	The percentage of patients experiencing device-related SAEs will be tabulated by arm.	Day 1
Primary	Assessment of withdrawals due to Adverse Events	The percentage of patients who withdraw due to an AE will be tabulated by arm.	Day 1
Primary	Assessment of reported and observed Serious Adverse Events	The percentage of patients experiencing SAEs will be tabulated by arm.	Week 1
Primary	Assessment of treatment-related Serious Adverse Events	The percentage of patients experiencing device-related SAEs will be tabulated by arm.	Week 1
Primary	Assessment of withdrawals due to Adverse Events	The percentage of patients who withdraw due to an AE will be tabulated by arm.	Week 1
Primary	Assessment of reported and observed Serious Adverse Events	The percentage of patients experiencing SAEs will be tabulated by arm.	Week 4
Primary	Assessment of treatment-related Serious Adverse Events	The percentage of patients experiencing device-related SAEs will be tabulated by arm.	Week 4
Primary	Assessment of withdrawals due to Adverse Events	The percentage of patients who withdraw due to an AE will be tabulated by arm.	Week 4
Primary	Assessment of reported and observed Serious Adverse Events	The percentage of patients experiencing SAEs will be tabulated by arm.	Week 8
Primary	Assessment of treatment-related Serious Adverse Events	The percentage of patients experiencing device-related SAEs will be tabulated by arm.	Week 8
Primary	Assessment of withdrawals due to Adverse Events	The percentage of patients who withdraw due to an AE will be tabulated by arm	Week 8
Primary	Assessment of reported and observed Adverse Events	The percentage of patients experiencing SAEs will be tabulated by arm.	Week 12
Primary	Assessment of treatment-related Serious Adverse Events	The percentage of patients experiencing device-related SAEs will be tabulated by arm.	Week 12
Primary	Assessment of withdrawals due to Adverse Events	The percentage of patients who withdraw due to an AE will be tabulated by arm.	Week 12
Secondary	Assessment of changes in blood endotoxin activity	The changes from baseline in blood endotoxin activity, measured by the EAA, will be used as device-related performance indicator.	The EAA will be performed at randomization, 1-week, 4-week, 8-week and 12-week visits.
Secondary	Assessment of changes in organ function as per the CHILD-PUGH score	Changes from baseline in kidney, liver, brain, intestinal and immune functions will be assessed by means of the CHILD-PUGH score.	CHILD-PUGH scores will be calculated at screening, randomization, 1-week, 4-week, 8-week and 12-week visits.
Secondary	Assessment of changes in organ function as per the MELD score	Changes from baseline in kidney, liver, brain, intestinal and immune functions will be assessed by means of the MELD score.	MELD scores will be calculated at screening, randomization, 1-week, 4-week, 8-week and 12-week visits.
Secondary	Assessment of changes in nutritional status	Changes from baseline in nutritional status be assessed by means of the global assessment score (RFH-GA);	Global assessment will be performed at randomization, 1-week, 4-week, 8-week and 12-week visits.